Co-Authors
This is a "connection" page, showing publications co-authored by ANITA DESWAL and CEZAR ILIESCU.
Connection Strength
2.172
-
Navigating P2Y12 inhibition in the labyrinth of cardio-oncology care: cangrelor bridging in patients with cancer. Front Cardiovasc Med. 2024; 11:1337957.
Score: 0.238
-
Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med. 2022; 9:1072890.
Score: 0.220
-
Myocardial Dysfunction in Patients with Cancer. Heart Fail Clin. 2022 Jul; 18(3):361-374.
Score: 0.212
-
Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis. Front Cardiovasc Med. 2022; 9:916325.
Score: 0.211
-
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021 10; 23(10):1725-1735.
Score: 0.197
-
Lenalidomide-Induced Myocarditis, Rare?But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. JACC Case Rep. 2020 Nov; 2(13):2095-2100.
Score: 0.188
-
Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. Int J Cardiol. 2020 08 15; 313:1-8.
Score: 0.182
-
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020 01 21; 9(2):e013757.
Score: 0.179
-
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
Score: 0.061
-
Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. J Nucl Cardiol. 2024 Sep; 39:101909.
Score: 0.061
-
Elevated IL-6 and Tumor Necrosis Factor-a in Immune Checkpoint Inhibitor Myocarditis. Diseases. 2024 May 03; 12(5).
Score: 0.060
-
Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure. Cardiovasc Drugs Ther. 2024 Jan 15.
Score: 0.059
-
Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis. Front Cardiovasc Med. 2022; 9:1073804.
Score: 0.055
-
Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer. JACC CardioOncol. 2022 Sep; 4(3):341-350.
Score: 0.054
-
Acute coronary syndrome in patients with cancer. Expert Rev Cardiovasc Ther. 2022 Apr; 20(4):275-290.
Score: 0.052
-
Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. Front Cardiovasc Med. 2021; 8:734820.
Score: 0.051
-
Rate of Progression of Aortic Stenosis in Patients With Cancer. Front Cardiovasc Med. 2021; 8:644264.
Score: 0.048
-
Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. J Immunother Precis Oncol. 2020 Aug; 3(3):113-120.
Score: 0.046